| Key TakeawaysGLP-1 and GIP are gut hormones with different jobs. GLP-1 slows digestion and curbs appetite, while GIP improves insulin sensitivity and regulates fat storage.Tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors. Semaglutide (Ozempic, Wegovy) activates only GLP-1.In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% body weight loss vs 13.7% with semaglutide over 72 weeks. |
The shift from single-hormone GLP-1 therapy to dual GLP-1/GIP agonism is one of the most consequential breakthroughs in obesity and type 2 diabetes care over the past decade. The science behind why activating both receptors changes outcomes comes down to how each hormone works inside the body.
GLP-1 vs GIP: Two Incretin Hormones, Two Distinct Roles
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are the two main incretin hormones. Together, they account for up to 70% of post-meal insulin secretion in healthy adults.
GIP is secreted by K-cells in the upper small intestine. GLP-1 comes from L-cells located lower in the small intestine and the colon. Both are released within minutes of food entering the gut, but they act on different organs and solve different metabolic problems. This functional split is well documented in a review published in the Journal of Diabetes Investigation.
Both hormones share one job: they stimulate glucose-dependent insulin release from pancreatic beta cells. That means insulin only spikes when blood sugar is high, which protects against hypoglycemia. Beyond that shared role, the two hormones diverge sharply.
| Feature | GLP-1 | GIP |
|---|---|---|
| Source cells | L-cells (distal small intestine, colon) | K-cells (upper small intestine) |
| Insulin secretion (glucose-dependent) | Yes, strong | Yes, the primary native incretin |
| Glucagon effect | Suppresses (during hyperglycemia) | Increases (during hypoglycemia, protective) |
| Gastric emptying | Slows substantially | No meaningful effect |
| Appetite suppression in the brain | Strong (hypothalamus, brainstem) | Modest, supports GLP-1 action |
| Adipose tissue | Indirect lipolysis | Direct insulin sensitization, healthy fat storage |
| Nausea and aversion signals | Triggers them via brainstem CCK neurons | Dampens them |
Notice the last two rows. They are the foundation of why dual agonism works better than GLP-1 alone.
How GLP-1 Receptor Agonists Like Ozempic Work
Semaglutide is sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management. It is a long-acting GLP-1 receptor agonist.
When it binds to the GLP-1 receptor, it triggers a chain of effects that explain its strong results in both glycemic control and weight loss.
Three mechanisms drive the outcomes:
- Slowed gastric emptying. Food sits longer in the stomach. You feel full sooner and eat less per meal.
- Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem cut hunger signalling, reducing daily energy intake.
- Glucose-dependent insulin release with glucagon suppression. Postprandial blood sugar drops without increasing the risk of low blood sugar episodes.
In the STEP-1 trial, semaglutide 2.4 mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. This was a meaningful jump over earlier GLP-1 therapies. But it also hit a ceiling. Most patients on semaglutide plateau between 12% and 16% weight loss, as confirmed in pooled analyses across the STEP and SUSTAIN clinical programmes.
A single-receptor approach has structural limits.
The GIP Receptor: What It Does That GLP-1 Cannot
GIP was historically dismissed as a weight-loss target. Early research suggested GIP promoted fat storage, which seemed counterproductive. That view has been overturned by mechanistic work over the past five years.
Three findings reshaped the science:
- GIP improves insulin sensitivity through adipose tissue. Adipose tissue expresses the GIP receptor; muscle and liver do not. When GIP is activated, it enhances glucose uptake into healthy fat stores. This effect is independent of weight loss.
- GIP supports healthy fat storage, not unhealthy fat accumulation. Instead of letting lipids spill into the liver, muscle, and visceral compartments, GIP promotes storage in subcutaneous fat depots. This protects against insulin resistance.
- GIP reduces nausea. GIP receptor activation in the area postrema and nucleus tractus solitarius (the brainstem regions that govern nausea) appears to dampen the aversive signals that GLP-1 produces.
The insulin-sensitization finding came from a 2021 study published in the Journal of Clinical Investigation, which used GLP-1 receptor knockout mice to isolate GIP’s effect. Tirzepatide improved insulin sensitivity even when GLP-1 signalling was completely absent.
The nausea-modulation finding was demonstrated in a Molecular Metabolism paper from 2022, which showed that GIP receptor activation reduces recruitment of brainstem cholecystokinin neurons that mediate food aversion.
Taken together, GIP does three things GLP-1 cannot do well on its own: it sensitizes adipose tissue to insulin, it protects against ectopic fat deposition, and it counteracts the nausea that limits GLP-1 dosing.
How Tirzepatide’s Dual Action Creates Synergy
Tirzepatide is a 39-amino acid peptide engineered from the native GIP sequence. It activates both the GIP receptor and the GLP-1 receptor with different potencies. It binds GIPR with affinity close to native GIP and GLP-1R with weaker but still meaningful activity. This is described as biased or imbalanced agonism. For a full primer on what is tirzepatide and the head-to-head trial data behind Mounjaro, see our dedicated drug guide.
The combined effect is not simply additive. Multiple lines of evidence suggest the two pathways amplify one another:
- Combined activation produces a cAMP response in pancreatic beta cells that exceeds either agonist alone, which means stronger insulin release for the same glucose level.
- Adipose tissue insulin sensitization (from GIP) plus appetite suppression (from GLP-1) acts on different sides of the energy balance equation. One reduces intake, the other improves how excess energy is stored.
- GIP receptor activity in the brainstem partially blocks the nausea and food aversion caused by GLP-1, which allows higher effective dosing without intolerable side effects.
This is why some researchers now describe tirzepatide as a “super GLP-1RA.” GIP receptor activation potentiates GLP-1’s effects rather than running on a separate parallel track.
The synergy was reviewed in detail in Cell Metabolism, 2023 and in a Frontiers in Endocrinology paper from 2024.
SURPASS-2 and SURMOUNT-5: What the Head-to-Head Trials Showed
Two pivotal randomized controlled trials directly compared tirzepatide and semaglutide. They are the only head-to-head data that matters when comparing the two drugs.
SURPASS-2: Type 2 diabetes, 40 weeks
Published in the New England Journal of Medicine in 2021, SURPASS-2 randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin to tirzepatide 5, 10, or 15 mg or semaglutide 1 mg. All three tirzepatide doses were superior to semaglutide on both HbA1c and body weight reductions. The 15 mg tirzepatide group reached an HbA1c reduction of 2.30 percentage points vs 1.86 with semaglutide.
SURMOUNT-5: Obesity without diabetes, 72 weeks
Published in NEJM in May 2025, SURMOUNT-5 was the first direct comparison of tirzepatide and semaglutide for weight management. It enrolled 751 adults with obesity (or overweight plus at least one weight-related comorbidity) without diabetes. Participants were randomized to maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks.
The results were unambiguous:
| SURMOUNT-5 Endpoint (72 weeks) | Tirzepatide | Semaglutide |
|---|---|---|
| Mean body weight change | −20.2% | −13.7% |
| Mean weight loss (kg) | −22.8 kg | −15.0 kg |
| Waist circumference change | −18.4 cm | −13.0 cm |
| BMI change | −8.0 kg/m² | −5.3 kg/m² |
| Achieved ≥10% weight loss | 81.6% | 60.5% |
| Achieved ≥15% weight loss | 64.6% | 40.1% |
| Achieved ≥20% weight loss | 48.4% | 27.3% |
| Achieved ≥25% weight loss | 31.6% | 16.1% |
Tirzepatide produced 47% greater relative weight loss than semaglutide at the highest tolerated doses. The difference was consistent across subgroups including sex, age, baseline BMI, and presence of cardiometabolic comorbidities.
Tirzepatide also delivered greater improvements in cardiometabolic markers including systolic and diastolic blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol, as documented in a real-world cohort study published in BMC Medicine.
Side Effects and Safety: GIP’s Unexpected Role in Tolerability
The side effect profile is where the science delivers a counterintuitive result. The more potent drug is also better tolerated for gastrointestinal symptoms in some comparisons. For a deeper look at tirzepatide vs semaglutide across the full side-effect spectrum, see our complete comparison.
In SURMOUNT-5, the discontinuation rate due to gastrointestinal side effects was 2.7% with tirzepatide versus 5.4% with semaglutide. Vomiting was less common with tirzepatide. Most adverse events were mild to moderate and concentrated during the dose-escalation phase, which lasts roughly 16 to 20 weeks.
Why does the dual agonist appear to be better tolerated despite stronger metabolic effects?
The leading explanation is GIP’s role in dampening nausea pathways, as discussed in Section 3. However, the tradeoff is not zero. Tirzepatide produces more injection site reactions, and a recent network meta-analysis in type 2 diabetes populations found tirzepatide had higher overall GI event rates than some other GLP-1 RAs at comparable diabetes-indication doses.
| Side Effect | Tirzepatide (high dose) | Semaglutide 2.4 mg |
|---|---|---|
| Nausea | About 24% to 33% | About 44% |
| Vomiting | About 9% to 13% | About 24% |
| Diarrhea | About 13% to 19% | About 30% |
| Constipation | About 11% to 17% | About 24% |
| GI-related discontinuation (SURMOUNT-5) | 2.7% | 5.4% |
| Injection site reactions | Higher than semaglutide | Lower than tirzepatide |
Important shared considerations apply to both drugs:
- Both can cause loss of lean body mass alongside fat loss. Resistance training and adequate protein intake (about 1.2 to 1.6 grams per kilogram of body weight) help preserve muscle.
- Both carry boxed warnings for thyroid C-cell tumors (based on rodent data). They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Both require slow dose escalation over weeks to minimize gastrointestinal symptoms.
- Pregnancy, pancreatitis history, and severe gastroparesis are key contraindications. Always discuss complete medical history with a qualified healthcare professional before starting either medication.
What Dual Incretin Therapy Means in the Indian Clinical Context
Mounjaro (tirzepatide) was approved by India’s Central Drugs Standard Control Organisation (CDSCO) and launched in March 2025.
It is approved for type 2 diabetes and for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease.
Ozempic (semaglutide) for diabetes, Rybelsus (oral semaglutide), and Wegovy (semaglutide 2.4 mg for chronic weight management) are also available in India.
Semaglutide has a longer real-world track record in clinical practice and a substantial cardiovascular outcomes dataset (SUSTAIN-6, SELECT).
Several India-specific considerations matter when choosing between these therapies:
- BMI thresholds for South Asians are generally lower than for Western populations. Many endocrinologists use a BMI cutoff of 25 for overweight and 27.5 for obesity in adults of Indian ethnicity, given higher visceral adiposity at lower body weight.
- Dietary patterns in many Indian households are carbohydrate-dominant and rely heavily on refined grains. The postprandial glucose response to large rice or roti meals interacts directly with how incretin therapy controls blood sugar. Pairing therapy with meal sequencing and protein-forward portions tends to improve outcomes.
- Sedentary work patterns and late dinner timing are common contributors to insulin resistance. These behavioural factors do not respond to medication alone and must be addressed alongside drug therapy for sustained results.
- Both drugs require lifelong commitment for sustained weight loss. Discontinuation typically results in regaining most of the lost weight within 12 to 18 months, as documented in the STEP-4 extension data.
- Cardiovascular outcomes data favours semaglutide today. Tirzepatide has not yet completed its dedicated CV outcomes trial (SURPASS-CVOT), although interim and observational data are encouraging.
Bottom Line
| GLP-1 and GIP are different incretin hormones with complementary roles. Tirzepatide produces greater weight loss and HbA1c reductions than semaglutide in head-to-head trials because activating both receptors creates synergistic effects on appetite, insulin sensitivity, and adipose tissue function, with GIP also dampening the nausea pathway that limits GLP-1 dosing. Semaglutide remains a strong, well-established option with longer cardiovascular outcomes data. The choice should be made with a qualified endocrinologist or diabetologist after a full review of medical history, contraindications, and treatment goals. |
Frequently Asked Questions About GLP-1 vs GIP
Q1. What is the difference between GLP-1 and GIP hormones?
Ans. GLP-1 and GIP are both incretin hormones released from gut cells after meals, but they target different organs. GLP-1 mainly slows gastric emptying and reduces appetite by acting on the brain. GIP mainly enhances insulin sensitivity in adipose tissue and supports healthy fat storage. Both stimulate glucose-dependent insulin release from pancreatic beta cells.
Q2. Why does tirzepatide target both GLP-1 and GIP?
Ans. Activating both receptors produces synergistic, not just additive, effects. GLP-1 drives appetite reduction and gastric slowing. GIP improves insulin sensitivity and may reduce the nausea signals GLP-1 normally produces in the brainstem. The combined effect leads to greater weight loss, better glycemic control, and lower gastrointestinal discontinuation rates in head-to-head clinical trials.
Q3. Does GIP affect gastric emptying the same way GLP-1 does?
Ans. No. Unlike GLP-1, GIP does not significantly slow gastric emptying. Food moves through the stomach at a normal rate when only GIP receptors are activated. This is one of the clearest functional differences between the two incretin hormones and helps explain why pure GIP agonism does not produce the satiety effects associated with GLP-1 therapies.
Q4. Is tirzepatide always better than semaglutide?
Ans. Tirzepatide produces greater average weight loss and HbA1c reduction in head-to-head trials. However, semaglutide has longer real-world clinical experience and a stronger cardiovascular outcomes dataset. Treatment choice depends on individual goals, contraindications, comorbidities, and clinician judgement. Always discuss options with a qualified healthcare professional.
Q5. Can dual GLP-1/GIP therapy reverse type 2 diabetes?
Ans. Tirzepatide does not reverse type 2 diabetes, but it can produce sustained remission of hyperglycemia in some patients with shorter disease duration. In SURPASS-2, several patients on tirzepatide achieved HbA1c levels below 5.7% without hypoglycemia, which is the non-diabetic range. Long-term data on durable remission is still being collected.
Sources and References
All claims in this article are grounded in primary peer-reviewed research and regulatory documents. Full source list below.
1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. https://www.appliedclinicaltrialsonline.com/view/tirzepatide-weight-loss-semaglutide-surmount-trial
3. Samms RJ, Christe ME, Collins KL, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation, 2021. https://pubmed.ncbi.nlm.nih.gov/34003802/
4. Borner T, Geisler CE, Fortin SM, et al. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis. Molecular Metabolism, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689241/
5. Wang G, Wu P, Qiu Y, Dong X, Wang Y, Chi Y, Zhang F, Li Y. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304055/
6. Müller TD, Adriaenssens A, Ahrén B, et al. Glucose-dependent insulinotropic polypeptide (GIP). Cell Metabolism, 2023. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00269-3
7. Killion EA, Lu SC, Fort M, et al. Chronic GIPR agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536395/
8. Yamane S, Inagaki N. Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity. Journal of Diabetes Investigation, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248429/
9. Killion EA, Coskun T, Sloop KW, Samms RJ. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes, 2025. https://diabetesjournals.org/diabetes/article/74/8/1326/160596/A-Contemporary-Rationale-for-Agonism-of-the-GIP
10. Cohort study comparing real-world weight reduction and cardiometabolic parameters with tirzepatide vs semaglutide. BMC Medicine, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924827/
11. Cardiovascular outcomes of semaglutide and tirzepatide in clinical practice (target trial emulation). Nature Cardiovascular Research, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12823426/
12. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Frontiers in Pharmacology, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491879/
13. Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control. Clinical and Translational Science, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496310/
14. Central Drugs Standard Control Organisation (CDSCO), Government of India. Approval records for tirzepatide. https://cdsco.gov.in/opencms/opencms/en/Home/
